Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.

Abstract: A computerized system of tracking health conditions of users associated with a client for diagnosing sleep apnea through forming an encrypted web based questionnaire. The user inputs information such as company personal information, individual personal information, health information, and personal health information. This information is then electronically compiled and a health screening service report is outputted such as witnessed sleep apnea, self admitted sleep apnea, body mass index of each user, and summary of results of a sleep test.

Abstract: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.

Abstract: A secure method for delivering sleep apnea diagnostic services on an at least one commercial driver to a trucking company. The sleep apnea diagnostic services are delivered by a general coordinator using a system. The system includes at least one processor connected to an input device, an output device, and a data storage. The data storage includes a plurality of secure computer instruction. The processor is in encrypted communication with a network which is in encrypted communication with at least one client device.

Abstract: Particular aspects of the inventive technology may, in embodiments, relate to a fluid filter apparatus that includes a filtered fluid conduit that has a length that is at least three times a characteristic diameter; and a plurality of holes, wherein at least one of said holes has a first shape and engages an end cap during fluid filter operation, and wherein at least one other of said holes has said first shape and passes filtered fluid from outside of said filtered fluid conduit to a conduit interior during fluid filter operation.

Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.

Abstract: A system for, and method of, permitting a client to locate a signing agent located within a desired area of a region is disclosed. A database is provided containing a listing of a plurality of signing agents dispersed over the region. The client is permitted to access the database to identify a signing agent located within the desired area of the region. The client is permitted to contact the identified signing agent to determine availability of the identified signing agent. The client is permitted to directly hire the identified signing agent if the identified signing agent is determined to be available. An additional signing agent is actively located if an available signing agent is not listed on the database.

Abstract: This invention provides the use of a combination of CCI-779 and an aromatase inhibitor in the treatment of neoplasms.